Abstract
The inhibition of immune checkpoint therapy emerged as the novel treatment in advanced lung cancer, including anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies. The fatal toxicity of anti-PD-1/PD-L1 agents is pneumonitis, which is defined as a noninfectious inflammation to the lung parenchyma. The diagnosis of pneumonitis consists of the history of immunotherapy, clinical symptoms and presentation of computed tomography (CT) imaging. The typical CT findings include ground-glass opacities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
